Bookmark
Forward
QuickView for Foscarnet (compound)
PubChem
| Name: | Foscarnet |
|---|---|
| PubChem Compound ID: | 169569 |
| Description: | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. |
| Molecular formula: | CH12Na3O11P |
| Molecular weight: | 300.042 g/mol |
| Synonyms: |
34156-56-4; D02267; Trisodium phosphonoformte hexahydrate; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; Formic acid, phosphono-, trisodium salt, hexahydrate; Foscarnet sodium hydrate; Foscarnet; Foscavir; Foscavir (TN); Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate.
show more » |
DrugBank
Identification
| Name: | Foscarnet |
|---|---|
| Name (isomeric): | DB00529 |
| Drug Type: | small molecule |
| Description: | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. |
| Synonyms: |
Phosphonoformate; Forscarnet sodium; Carboxyphosphonic acid; Foscarnet sodium; Dihydroxyphosphinecarboxylic acid oxide; Phgosphonocarboxylic acid; PFA; Phosphonoformic acid
|
| Brand: | Triapten, Foscavir, Foscarmet |
| Category: | Antiviral Agents, Reverse Transcriptase Inhibitors |
| CAS number: | 63585-09-1 |
Pharmacology
| Indication: | For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. |
|---|---|
| Pharmacology: |
Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK...
show more » |
| Mechanism of Action: | Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. |
| Absorption: | Poorly absorbed after oral administration (bioavailability from 12 to 22%). |
| Protein binding: | 14-17% |
| Biotransformation: | Not metabolized. |
| Half Life: | 3.3-6.8 hours |
| Clearance: | 2.13 +/- 0.71 mL/min/kg [patients had normal renal function (CrCl > 80 mL/min] 68 +/- 8 mL/min/kg [CrCl was 50-80 mL/min] 34 +/- 9 mL/min/kg [CrCl was 25-49 mL/min] 20 +/- 4 mL/min/kg [CrCl was 10 - 24 mL/min] |
| Toxicity: | Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment. |
| Affected organisms: | Human Herpes Virus |
Interactions
| Drug interaction: |
|
|---|
Targets
Transporters
